Antiangiogenic therapy in pancreatic neuroendocrine tumors

Monica Capozzi, Claudia Von Arx, Chiara De Divitiis, Alessandro Ottaiano, Fabiana Tatangelo, Giovanni Maria Romano, Salvatore Tafuto

Research output: Contribution to journalReview article

Abstract

In recent years, many progresses have been pursued in the management of advanced pancreatic neuroendocrine tumor (pNET); most of them were prompted by increasing knowledge of biology of these neoplasms, including the identification of promising biological targets for therapy. PNETs belong to a group of rare neoplastic diseases. They originate from neuroendocrine system cells and are very heterogeneous regarding anatomic localization and aggressiveness. Recently, many efforts have been particularly focused on the identification of pathologic pathways and innovative drugs in order to treat patients with unresectable, metastatic disease, in progressive well-differentiated pNETs. Chemotherapy remains the mainstay of treatment of poorly-differentiated pNETs. The positive results obtained by sunitinib, a multi-targeted tyrosine kinase receptor inhibitor of vascular endothelial growth factor receptor (VEGFR) 1-3, platelet-derived growth factor receptor (PDGFR), c-kit, RET, colony stimulating factor-1 receptor (CSF-1R) and Fms-like tyrosine kinase 3 (FLT3), with direct antitumor and antiangiogenic effects, have highlighted the importance of tumor angiogenesis inhibition in controlling these tumors. Angiogenesis is a crucial process during tumor progression and plays a key role in development of metastasis.

Original languageEnglish
Pages (from-to)5025-5030
Number of pages6
JournalAnticancer Research
Volume36
Issue number10
DOIs
Publication statusPublished - Oct 1 2016

Fingerprint

Neuroendocrine Tumors
Neoplasms
fms-Like Tyrosine Kinase 3
Colony-Stimulating Factor Receptors
Vascular Endothelial Growth Factor Receptor-3
Vascular Endothelial Growth Factor Receptor-1
Primitive Neuroectodermal Tumors
Platelet-Derived Growth Factor Receptors
Neuroendocrine Cells
Neurosecretory Systems
Biological Therapy
Macrophage Colony-Stimulating Factor
Receptor Protein-Tyrosine Kinases
Therapeutics
Rare Diseases
Neoplasm Metastasis
Drug Therapy
Pharmaceutical Preparations

Keywords

  • Angiogenesis
  • Bevacizumab
  • Neuroendocrine tumors
  • Review
  • Sunitinib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Antiangiogenic therapy in pancreatic neuroendocrine tumors. / Capozzi, Monica; Von Arx, Claudia; De Divitiis, Chiara; Ottaiano, Alessandro; Tatangelo, Fabiana; Romano, Giovanni Maria; Tafuto, Salvatore.

In: Anticancer Research, Vol. 36, No. 10, 01.10.2016, p. 5025-5030.

Research output: Contribution to journalReview article

@article{d49946706ab147bab66063b73d20cbb7,
title = "Antiangiogenic therapy in pancreatic neuroendocrine tumors",
abstract = "In recent years, many progresses have been pursued in the management of advanced pancreatic neuroendocrine tumor (pNET); most of them were prompted by increasing knowledge of biology of these neoplasms, including the identification of promising biological targets for therapy. PNETs belong to a group of rare neoplastic diseases. They originate from neuroendocrine system cells and are very heterogeneous regarding anatomic localization and aggressiveness. Recently, many efforts have been particularly focused on the identification of pathologic pathways and innovative drugs in order to treat patients with unresectable, metastatic disease, in progressive well-differentiated pNETs. Chemotherapy remains the mainstay of treatment of poorly-differentiated pNETs. The positive results obtained by sunitinib, a multi-targeted tyrosine kinase receptor inhibitor of vascular endothelial growth factor receptor (VEGFR) 1-3, platelet-derived growth factor receptor (PDGFR), c-kit, RET, colony stimulating factor-1 receptor (CSF-1R) and Fms-like tyrosine kinase 3 (FLT3), with direct antitumor and antiangiogenic effects, have highlighted the importance of tumor angiogenesis inhibition in controlling these tumors. Angiogenesis is a crucial process during tumor progression and plays a key role in development of metastasis.",
keywords = "Angiogenesis, Bevacizumab, Neuroendocrine tumors, Review, Sunitinib",
author = "Monica Capozzi and {Von Arx}, Claudia and {De Divitiis}, Chiara and Alessandro Ottaiano and Fabiana Tatangelo and Romano, {Giovanni Maria} and Salvatore Tafuto",
year = "2016",
month = "10",
day = "1",
doi = "10.21873/anticanres.11071",
language = "English",
volume = "36",
pages = "5025--5030",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "10",

}

TY - JOUR

T1 - Antiangiogenic therapy in pancreatic neuroendocrine tumors

AU - Capozzi, Monica

AU - Von Arx, Claudia

AU - De Divitiis, Chiara

AU - Ottaiano, Alessandro

AU - Tatangelo, Fabiana

AU - Romano, Giovanni Maria

AU - Tafuto, Salvatore

PY - 2016/10/1

Y1 - 2016/10/1

N2 - In recent years, many progresses have been pursued in the management of advanced pancreatic neuroendocrine tumor (pNET); most of them were prompted by increasing knowledge of biology of these neoplasms, including the identification of promising biological targets for therapy. PNETs belong to a group of rare neoplastic diseases. They originate from neuroendocrine system cells and are very heterogeneous regarding anatomic localization and aggressiveness. Recently, many efforts have been particularly focused on the identification of pathologic pathways and innovative drugs in order to treat patients with unresectable, metastatic disease, in progressive well-differentiated pNETs. Chemotherapy remains the mainstay of treatment of poorly-differentiated pNETs. The positive results obtained by sunitinib, a multi-targeted tyrosine kinase receptor inhibitor of vascular endothelial growth factor receptor (VEGFR) 1-3, platelet-derived growth factor receptor (PDGFR), c-kit, RET, colony stimulating factor-1 receptor (CSF-1R) and Fms-like tyrosine kinase 3 (FLT3), with direct antitumor and antiangiogenic effects, have highlighted the importance of tumor angiogenesis inhibition in controlling these tumors. Angiogenesis is a crucial process during tumor progression and plays a key role in development of metastasis.

AB - In recent years, many progresses have been pursued in the management of advanced pancreatic neuroendocrine tumor (pNET); most of them were prompted by increasing knowledge of biology of these neoplasms, including the identification of promising biological targets for therapy. PNETs belong to a group of rare neoplastic diseases. They originate from neuroendocrine system cells and are very heterogeneous regarding anatomic localization and aggressiveness. Recently, many efforts have been particularly focused on the identification of pathologic pathways and innovative drugs in order to treat patients with unresectable, metastatic disease, in progressive well-differentiated pNETs. Chemotherapy remains the mainstay of treatment of poorly-differentiated pNETs. The positive results obtained by sunitinib, a multi-targeted tyrosine kinase receptor inhibitor of vascular endothelial growth factor receptor (VEGFR) 1-3, platelet-derived growth factor receptor (PDGFR), c-kit, RET, colony stimulating factor-1 receptor (CSF-1R) and Fms-like tyrosine kinase 3 (FLT3), with direct antitumor and antiangiogenic effects, have highlighted the importance of tumor angiogenesis inhibition in controlling these tumors. Angiogenesis is a crucial process during tumor progression and plays a key role in development of metastasis.

KW - Angiogenesis

KW - Bevacizumab

KW - Neuroendocrine tumors

KW - Review

KW - Sunitinib

UR - http://www.scopus.com/inward/record.url?scp=84991778546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991778546&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11071

DO - 10.21873/anticanres.11071

M3 - Review article

AN - SCOPUS:84991778546

VL - 36

SP - 5025

EP - 5030

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 10

ER -